Allarity Therapeutics, Inc. develops personalized cancer treatments as a clinical-stage biopharmaceutical company focused on stenoparib (2X-121), a dual PARP and WNT pathway inhibitor, and its DRP® companion diagnostic technology. The company’s updates center on Phase 2 oncology development, advanced ovarian cancer, clinical and scientific data presentations, companion-diagnostic intellectual property, FDA Fast Track status, and potential use of stenoparib in additional tumor settings.
Recurring news also covers operating and financial results, financing activity that supports clinical programs, research collaborations, and governance matters for the Nasdaq-listed company.
Allarity Therapeutics, Inc. announced the early discontinuation of its Phase 2 trial of stenoparib, a PARP inhibitor, for advanced ovarian cancer. The trial showed clear clinical benefit, prompting the company to halt enrollment and focus on a follow-on trial for FDA submission. The patients were pre-screened using Allarity's companion diagnostic for personalized treatment. CEO Thomas Jensen emphasized the substantial positive outcomes and the potential of stenoparib in heavily pre-treated patients.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.